Sanggenol L induces ferroptosis in non-small cell lung cancer cells via regulating the miR-26a-1-3p/MDM2/p53 signaling pathway
- 8 June 2024
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 226, 116345
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Lung cancer statistics, 2023Cancer, 2024
- SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cellsCancer Letters, 2021
- Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal CancerAdvanced Science, 2021
- miR-26 family and its target genes in tumorigenesis and developmentCritical Reviews in Oncology/Hematology, 2021
- Drug resistance in cancer: mechanisms and tackling strategiesPharmacological Reports, 2020
- Sanggenol L promotes apoptotic cell death in melanoma skin cancer cells through activation of caspase cascades and apoptosis-inducing factorFood and Chemical Toxicology, 2020
- Potential hepatoxicity risk of the shell of Herpetospermum caudigerum Wall in rats based on 1H-NMR metabonomicsJournal of Pharmaceutical and Biomedical Analysis, 2019
- Targeting Ferroptosis to Iron Out CancerCancer Cell, 2019
- Apoptotic Effect of Sanggenol L via Caspase Activation and Inhibition of NF-κB Signaling in Ovarian Cancer CellsPhytotherapy Research, 2015
- Isoprenylated flavonoids from the root bark of Morus alba and their hepatoprotective and neuroprotective activitiesArchives of Pharmacal Research, 2015